PBD Dimer Conjugates with Beta-Glucuronide Capping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PBD dimer conjugates face challenges in targeted drug delivery due to their hydrophobic nature, which affects their ability to permeate cell membranes and maintain activity outside the target cell, and existing linker systems do not efficiently facilitate controlled release and conjugation to cell binding agents.
Innovation Solution
The development of PBD dimer conjugates with a β-glucuronide capping group at the N10-C11 position, allowing for non-glucuronide cleavable linkers that increase hydrophilicity and facilitate conjugation to ligand units, such as antibodies, enabling targeted delivery and controlled release of the drug.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PBD dimer conjugates are designed with traditional linker systems, then conjugation to cell binding agents can be achieved, but the hydrophobic nature of the conjugates reduces their ability to permeate cell membranes and maintain activity outside the target cell
Solution Approach 1:
The patent introduces a β-glucuronide capping group as an intermediary component attached to the PBD dimer. This capping group acts as a hydrophilic mediator that reduces the overall hydrophobicity of the conjugate, enabling better solubility and membrane permeation while maintaining the cytotoxic activity of the PBD core when activated inside the target cell.
2Ease of operation
If PBD dimers are made more hydrophilic to improve membrane permeation, then cell delivery efficiency increases, but conjugation efficiency to ligand units may be reduced
Solution Approach 1:
The patent applies local quality modification by adding the β-glucuronide capping group specifically to the PBD dimer structure. This localized modification introduces hydrophilic character at a specific site without altering the core PBD structure responsible for DNA binding and cytotoxicity, thereby achieving improved solubility while preserving conjugation capabilities.
3Reliability
If traditional linker systems are used for PBD conjugates, then conjugation to antibodies is possible, but controlled release and targeted delivery are not efficiently achieved
Solution Approach 1:
The patent employs parameter changes by utilizing the β-glucuronide moiety's specific biochemical properties. The capping group can be metabolized by β-glucuronidase enzyme present in lysosomes, triggering controlled release of the active PBD drug inside the target cell. This enzymatic activation mechanism provides targeted delivery without requiring complex multi-component linker systems.
Data Source
Figure 1~2
Figure 3~4
AI summary
A compound of formula (I) : (I) and its conjugates.